SL-GD001 / JY Biomed, SL Science Holding Limited - LARVOL DELTA

SL Science Holding…announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). (The Manila Times) - "The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product...The research team of JY BioMed ('JY BioMed'), licensor of the Company’s GDT cell therapy technology will present at the 20th World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia....Designation Request Number: DRU-2026-11528."

Orphan drug • Preclinical • Glioblastoma